{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:31:11Z","timestamp":1790847071185,"version":"4.1.0"},"reference-count":100,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2017,10,8]],"date-time":"2017-10-08T00:00:00Z","timestamp":1507420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Poly (ADP-ribose) polymerase 1 (PARP1), the best-studied isoform of the nuclear enzyme PARP family, plays a pivotal role in cellular biological processes, such as DNA repair, gene transcription, and so on. PARP1 has been found to be overexpressed in various carcinomas. These all indicate the clinical potential of PARP1 as a therapeutic target of human malignancies. Additionally, multiple preclinical research studies and clinical trials demonstrate that inhibition of PARP1 can repress tumor growth and metastasis. Up until now, PARP1 inhibitors are clinically used not only for monotherapy to suppress various tumors, but also for adjuvant therapy, to maintain or enhance therapeutic effects of mature antineoplastic drugs, as well as protect patients from chemotherapy and surgery-induced injury. To supply a framework for understanding recent research progress of PARP1 in carcinomas, we review the structure, expression, functions, and mechanisms of PARP1, and summarize the clinically mature PARP1-related anticancer agents, to provide some ideas for the development of other promising PARP1 inhibitors in antineoplastic therapy.<\/jats:p>","DOI":"10.3390\/ijms18102111","type":"journal-article","created":{"date-parts":[[2017,10,9]],"date-time":"2017-10-09T11:25:35Z","timestamp":1507548335000},"page":"2111","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":105,"title":["PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs"],"prefix":"10.3390","volume":"18","author":[{"given":"Luyao","family":"Wang","sequence":"first","affiliation":[{"name":"Law Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China"},{"name":"Institute of Integrated Bioinfomedicine and Translational Science, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China"},{"name":"Institute of Precision Medicine and Innovative Drug Discovery, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China"},{"name":"Shenzhen Lab of Combinatorial Compounds and Targeted Drug Delivery, HKBU Institute of Research and Continuing Education, Shenzhen 518000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Liang","sequence":"additional","affiliation":[{"name":"Law Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China"},{"name":"Institute of Integrated Bioinfomedicine and Translational Science, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China"},{"name":"Institute of Precision Medicine and Innovative Drug Discovery, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China"},{"name":"Shenzhen Lab of Combinatorial Compounds and Targeted Drug Delivery, HKBU Institute of Research and Continuing Education, Shenzhen 518000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfei","family":"Li","sequence":"additional","affiliation":[{"name":"Law Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China"},{"name":"Institute of Integrated Bioinfomedicine and Translational Science, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China"},{"name":"Institute of Precision Medicine and Innovative Drug Discovery, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China"},{"name":"Shenzhen Lab of Combinatorial Compounds and Targeted Drug Delivery, HKBU Institute of Research and Continuing Education, Shenzhen 518000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3289-1448","authenticated-orcid":false,"given":"Daogang","family":"Guan","sequence":"additional","affiliation":[{"name":"Law Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China"},{"name":"Institute of Integrated Bioinfomedicine and Translational Science, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China"},{"name":"Institute of Precision Medicine and Innovative Drug Discovery, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China"},{"name":"Shenzhen Lab of Combinatorial Compounds and Targeted Drug Delivery, HKBU Institute of Research and Continuing Education, Shenzhen 518000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqiu","family":"Wu","sequence":"additional","affiliation":[{"name":"Law Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China"},{"name":"Institute of Integrated Bioinfomedicine and Translational Science, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China"},{"name":"Institute of Precision Medicine and Innovative Drug Discovery, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China"},{"name":"Shenzhen Lab of Combinatorial Compounds and Targeted Drug Delivery, HKBU Institute of Research and Continuing Education, Shenzhen 518000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuekun","family":"Fu","sequence":"additional","affiliation":[{"name":"Law Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China"},{"name":"Institute of Integrated Bioinfomedicine and Translational Science, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China"},{"name":"Institute of Precision Medicine and Innovative Drug Discovery, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China"},{"name":"Shenzhen Lab of Combinatorial Compounds and Targeted Drug Delivery, HKBU Institute of Research and Continuing Education, Shenzhen 518000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiping","family":"Lu","sequence":"additional","affiliation":[{"name":"Law Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China"},{"name":"Institute of Integrated Bioinfomedicine and Translational Science, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China"},{"name":"Institute of Precision Medicine and Innovative Drug Discovery, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China"},{"name":"Shenzhen Lab of Combinatorial Compounds and Targeted Drug Delivery, HKBU Institute of Research and Continuing Education, Shenzhen 518000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7807-7695","authenticated-orcid":false,"given":"Ge","family":"Zhang","sequence":"additional","affiliation":[{"name":"Law Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China"},{"name":"Institute of Integrated Bioinfomedicine and Translational Science, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China"},{"name":"Institute of Precision Medicine and Innovative Drug Discovery, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China"},{"name":"Shenzhen Lab of Combinatorial Compounds and Targeted Drug Delivery, HKBU Institute of Research and Continuing Education, Shenzhen 518000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2017,10,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J. Clin. Oncol"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1310\/hpx5203-258","article-title":"Drug Monographs: Olaratumab and Rucaparib","volume":"52","author":"Solimando","year":"2017","journal-title":"Hosp. Pharm."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"5626","DOI":"10.1158\/0008-5472.CAN-11-1227","article-title":"Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas","volume":"71","author":"Kummar","year":"2011","journal-title":"Cancer Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nrd1718","article-title":"Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors","volume":"4","author":"Jagtap","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3389\/fonc.2013.00290","article-title":"Beyond DNA Repair: Additional Functions of PARP-1 in Cancer","volume":"3","author":"Weaver","year":"2013","journal-title":"Front. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Hamilton, G. (2013). Advances in Prostate Cancer. The Role of PARP Activation in Prostate Cancer, InTech.","DOI":"10.5772\/45948"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1158\/1541-7786.MCR-16-0287-T","article-title":"Let-7 Status is crucial for PARP1 expression in HER2-over-expressing breast tumors","volume":"15","author":"Wielgos","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/356356a0","article-title":"Role of poly(ADP-ribose) formation in DNA repair","volume":"356","author":"Satoh","year":"1992","journal-title":"Nature"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.yexcr.2014.07.003","article-title":"Poly(ADP-ribose) polymerases in double-strand break repair: focus on PARP1, PARP2 and PARP3","volume":"329","author":"Beck","year":"2014","journal-title":"Exp. Cell Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1200\/JCO.2008.16.0812","article-title":"A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair","volume":"26","author":"Ashworth","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"i40","DOI":"10.1093\/annonc\/mdw094","article-title":"PARP inhibitors in ovarian cancer","volume":"27","author":"Ledermann","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"943","DOI":"10.3390\/cancers5030943","article-title":"PARP-1: Friend or Foe of DNA Damage and Repair in Tumorigenesis?","volume":"5","author":"Swindall","year":"2013","journal-title":"Cancers"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1158\/0008-5472.CAN-11-3648","article-title":"PARP-1 inhibition as a targeted strategy to treat Ewing\u2019s sarcoma","volume":"72","author":"Brenner","year":"2012","journal-title":"Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"4796","DOI":"10.1158\/0008-5472.CAN-12-1287","article-title":"HER2 overexpression renders human breast cancers sensitive to PARP inhibition independently of any defect in homologous recombination DNA repair","volume":"72","author":"Nowsheen","year":"2012","journal-title":"Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.32607\/20758251-2015-7-3-27-37","article-title":"PARP1 Inhibitors: antitumor drug design","volume":"7","author":"Malyuchenko","year":"2015","journal-title":"Acta Naturae."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nrc2812","article-title":"PARP inhibition: PARP1 and beyond","volume":"10","author":"Rouleau","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1126\/science.1216338","article-title":"Structural basis for DNA damage-dependent poly(ADP-ribosyl)ation by human PARP-1","volume":"336","author":"Langelier","year":"2012","journal-title":"Science"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nsmb.2335","article-title":"The zinc-finger domains of PARP1 cooperate to recognize DNA strand breaks","volume":"19","author":"Ali","year":"2012","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5804","DOI":"10.1021\/bi800018a","article-title":"Domain C of Human Poly(ADP-ribose) Polymerase-1 Is Important for Enzyme Activity and Contains a Novel Zinc-Ribbon Motif","volume":"47","author":"Tao","year":"2008","journal-title":"Biochemistry"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Loeffler, P.A., Cuneo, M.J., Mueller, G.A., DeRose, E.F., Gabel, S.A., and London, R.E. (2011). Structural studies of the PARP-1 BRCT domain. BMC Struct. Biol., 11.","DOI":"10.1186\/1472-6807-11-37"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrm.2017.53","article-title":"The multifaceted roles of PARP1 in DNA repair and chromatin remodelling","volume":"18","author":"Nussenzweig","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.molcel.2015.10.032","article-title":"Structural Basis of Detection and Signaling of DNA Single-Strand Breaks by Human PARP-1","volume":"60","author":"Eustermann","year":"2015","journal-title":"Mol. Cell"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1177\/1947601910383418","article-title":"Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types","volume":"1","author":"Ossovskaya","year":"2010","journal-title":"Genes Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s10549-011-1441-2","article-title":"PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy","volume":"127","author":"Domagala","year":"2011","journal-title":"Breast Cancer Res. Treat"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.3892\/or.2014.3024","article-title":"Nuclear-cytoplasmic PARP-1 expression as an unfavorable prognostic marker in lymph nodenegative early breast cancer: 15-year follow-up","volume":"31","author":"Donizy","year":"2014","journal-title":"Oncol. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"6143","DOI":"10.1007\/s13277-015-4465-0","article-title":"Nuclear PARP1 expression and its prognostic significance in breast cancer patients","volume":"37","author":"Mazzotta","year":"2016","journal-title":"Tumor Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1158\/2159-8290.CD-12-0112","article-title":"Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1","volume":"2","author":"Byers","year":"2012","journal-title":"Cancer Discov."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.4081\/ejh.2012.e9","article-title":"PARP-1 protein expression in glioblastoma multiforme","volume":"56","author":"Galia","year":"2012","journal-title":"Eur. J. Histochem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1158\/2159-8290.CD-12-0120","article-title":"Dual roles of PARP-1 promote cancer growth and progression","volume":"2","author":"Schiewer","year":"2012","journal-title":"Cancer Discov."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1016\/j.ejca.2006.01.061","article-title":"Overexpression of poly(ADP-ribose) polymerase-1 (PARP-1) in the early stage of colorectal carcinogenesis","volume":"42","author":"Nosho","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/pbc.22141","article-title":"PARP1 Expression in Pediatric Central Nervous System Tumors","volume":"53","author":"Barton","year":"2009","journal-title":"Pediatric. Blood Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1136\/jclinpath-2012-201088","article-title":"PARP expression in germ cell tumours","volume":"66","author":"Mego","year":"2013","journal-title":"J Clin Pathol"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.gpb.2016.05.001","article-title":"Functions of PARylation in DNA Damage Repair Pathways","volume":"14","author":"Wei","year":"2016","journal-title":"Genomics Proteomics Bioinformatics"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1126\/science.aaf7865","article-title":"Chemical genetic discovery of PARP targets reveals a role for PARP-1 in transcription elongation","volume":"353","author":"Gibson","year":"2016","journal-title":"Science"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ceb.2008.03.006","article-title":"Transcriptional control by PARP-1: chromatin modulation, enhancer-binding, coregulation, and insulation","volume":"20","author":"Kraus","year":"2008","journal-title":"Curr. Opin. Cell Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/hep.23249","article-title":"Inhibition of poly adenosine diphosphate-ribose polymerase decreases hepatocellular carcinoma growth by modulation of tumor-related gene expression","volume":"51","author":"Caballero","year":"2010","journal-title":"Hepatology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5744","DOI":"10.1158\/0008-5472.CAN-05-3050","article-title":"Inhibition of poly(ADP-ribose) polymerase modulates tumor-related gene expression, including hypoxia-inducible factor-1 activation, during skin carcinogenesis","volume":"66","author":"Villuendas","year":"2006","journal-title":"Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1038\/ng.3927","article-title":"A common intronic variant of PARP1 confers melanoma risk and mediates melanocyte growth via regulation of MITF","volume":"49","author":"Choi","year":"2017","journal-title":"Nature Genetics"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"9366","DOI":"10.1074\/jbc.M009897200","article-title":"A role for poly(ADP-ribose) polymerase in the transcriptional regulation of the melanoma growth stimulatory activity (CXCL1) gene expression","volume":"276","author":"Nirodi","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/1541-7786.MCR-13-0672","article-title":"Transcriptional roles of PARP1 in cancer","volume":"12","author":"Schiewer","year":"2014","journal-title":"Mol Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"18914","DOI":"10.1074\/jbc.M211641200","article-title":"Poly(ADP-ribose) polymerase-1 is a positive regulator of the p53-mediated G1 arrest response following ionizing radiation","volume":"278","author":"Wieler","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.molcel.2015.04.016","article-title":"Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function","volume":"58","author":"Feng","year":"2015","journal-title":"Mol. Cell"},{"key":"ref_45","first-page":"560","article-title":"Chromatin Loosening by Poly(ADP)-Ribose Polymerase (PARP) at Drosophila Puff Loci","volume":"299","author":"Tulin","year":"2003","journal-title":"Science reports"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S0301-472X(03)00083-3","article-title":"PARP-1, a determinant of cell survival in response to DNA damage","volume":"31","author":"Bouchard","year":"2003","journal-title":"Exp. Hematol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1042\/bj3420249","article-title":"Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions","volume":"342","author":"Desnoyers","year":"1999","journal-title":"Biochem. J."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.mam.2013.01.005","article-title":"PARP-1 and gene regulation: progress and puzzles","volume":"34","author":"Kraus","year":"2013","journal-title":"Mol. Aspects Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"33926","DOI":"10.1074\/jbc.M109.023879","article-title":"Global analysis of transcriptional regulation by poly(ADP-ribose) polymerase-1 and poly(ADP-ribose) glycohydrolase in MCF-7 human breast cancer cells","volume":"284","author":"Frizzell","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/sj.onc.1208005","article-title":"Modulation of DNMT1 activity by ADP-ribose polymers","volume":"24","author":"Reale","year":"2005","journal-title":"Oncogene"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1476-4598-12-86","article-title":"The complexity of NF-\u03baB signaling in inflammation and cancer","volume":"12","author":"Hoesel","year":"2013","journal-title":"Mol. Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/sj.bjp.0706837","article-title":"Anti-inflammatory effects of PJ34, a poly(ADP-ribose) polymerase inhibitor, in transient focal cerebral ischemia in mice","volume":"149","author":"Haddad","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-2776(06)90001-7","article-title":"Cancer Immunosurveillance and Immunoediting: The Roles of Immunity in Suppressing Tumor Development and Shaping Tumor Immunogenicity","volume":"90","author":"Smyth","year":"2006","journal-title":"Adv. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/jcp.22402","article-title":"Expression pattern of receptor activator of NFkappaB (RANK) in a series of primary solid tumors and related bone metastases","volume":"226","author":"Santini","year":"2011","journal-title":"J. Cell Physiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"15852","DOI":"10.1073\/pnas.0706728104","article-title":"I\u03baB kinase \u03b1 kinase activity is required for self-renewal of ErbB2\/Her2-transformed mammary tumor-initiating cells","volume":"104","author":"Cao","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1177\/1091581812457430","article-title":"Potential role of poly(ADP-ribose) polymerase (PARP) activation in methotrexate-induced nephrotoxicity and tubular apoptosis","volume":"31","author":"Dalaklioglu","year":"2012","journal-title":"Int. J. Toxicol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/nature03061","article-title":"Poly(ADP-ribose) is required for spindle assembly and structure","volume":"432","author":"Chang","year":"2004","journal-title":"Nature"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/1097-4644(20001201)79:3<355::AID-JCB20>3.0.CO;2-0","article-title":"MEK\/ERK Signaling Pathway Regulates the Expression of Bcl-2, Bcl-XL, and Mcl-1 and Promotes Survival of Human Pancreatic Cancer Cells","volume":"79","author":"Boucher","year":"2000","journal-title":"J. Cell. Biochem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/sj.cdd.4402088","article-title":"c-Jun N-terminal kinase mediates hydrogen peroxide-induced cell death via sustained poly(ADP-ribose) polymerase-1 activation","volume":"14","author":"Zhang","year":"2007","journal-title":"Cell. Death. Differ."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"11274","DOI":"10.1073\/pnas.200285797","article-title":"Misregulation of gene expression in primary fibroblasts lacking poly(ADP-ribose) polymerase","volume":"97","author":"Ly","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_61","first-page":"861","article-title":"Pharmacological inhibition of poly(ADP-ribose) polymerase activity down-regulates the expression of syndecan-4 and Id-1 in endothelial cells","volume":"34","author":"Lacal","year":"2009","journal-title":"Int. J. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.bbrc.2006.09.160","article-title":"Poly(ADP-ribose)polymerase inhibition decreases angiogenesis","volume":"350","author":"Rajesh","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"4561","DOI":"10.3892\/ol.2016.5226","article-title":"PARP-1 may be involved in angiogenesis in epithelial ovarian cancer","volume":"12","author":"Wei","year":"2016","journal-title":"Oncol. Lett."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Rodriguez, M.I., Peralta-Leal, A., O\u2019Valle, F., Rodriguez-Vargas, J.M., Gonzalez-Flores, A., Majuelos-Melguizo, J., L\u00f3pez, L., Serrano, S., de Herreros, A.G., and Rodr\u00edguez-Manzaneque, J.-C. (2013). PARP-1 regulates metastatic melanoma through modulation of vimentin-induced malignant transformation. PLoS Genet., 9.","DOI":"10.1371\/journal.pgen.1003531"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1038\/onc.2016.3","article-title":"PARP1 enhances lung adenocarcinoma metastasis by novel mechanisms independent of DNA repair","volume":"35","author":"Choi","year":"2016","journal-title":"Oncogene"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.mam.2013.01.006","article-title":"Therapeutic applications of PARP inhibitors: anticancer therapy and beyond","volume":"34","author":"Curtin","year":"2013","journal-title":"Mol. Aspects Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.molonc.2011.07.001","article-title":"The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings","volume":"5","author":"Helleday","year":"2011","journal-title":"Mol. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1042\/bj1850775","article-title":"Novel Inhibitors of Poly(ADP-Ribose) Synthetase","volume":"185","author":"Purnell","year":"1980","journal-title":"Biochem. J."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1517\/13543770903215883","article-title":"Poly(ADP-ribose) polymerase inhibition in cancer therapy: Are we close to maturity?","volume":"19","author":"Papeo","year":"2009","journal-title":"Expert. Opin. Ther. Pat."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0009-2797(82)90062-X","article-title":"Potentiation of cell killing by inhibitors of poly (ADP-ribose) polymerase in four rodent cell lines exposed to N-methyl-N-nitrosourea or UV light","volume":"38","author":"Durrant","year":"1982","journal-title":"Chem. Biol. Inter."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1158\/1078-0432.CCR-15-0887","article-title":"FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy","volume":"21","author":"Kim","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/jps.23952","article-title":"PARP Inhibitors as P-glyoprotein Substrates","volume":"103","author":"Lawlor","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Gilabert, M., Launay, S., Ginestier, C., Bertucci, F., Audebert, S., Pophillat, M., Toiron, Y., Baudelet, E., Finetti, P., Noguchi, T., and Sobol, H. (2014). Poly(ADP-Ribose) Polymerase 1 (PARP1) Overexpression in Human Breast Cancer Stem Cells and Resistance to Olaparib. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0104302"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_77","first-page":"201","article-title":"Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited","volume":"1846","author":"Lupo","year":"2014","journal-title":"Biochim. Biophys. Acta."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.2147\/OTT.S114714","article-title":"Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer","volume":"10","author":"Dockery","year":"2017","journal-title":"Onco Targets Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"S531","DOI":"10.1016\/S0959-8049(16)31469-1","article-title":"Quantification of genomic loss of heterozygosity enables prospective selection of ovarian cancer patients who may derive benefit from the PARP inhibitor rucaparib","volume":"51","author":"Lin","year":"2015","journal-title":"Europ. Cancer Congr."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1158\/1535-7163.MCT-12-0813","article-title":"Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer","volume":"12","author":"Ihnen","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1158\/1078-0432.CCR-16-3068","article-title":"The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma","volume":"23","author":"Soumerai","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1158\/1078-0432.CCR-16-2714","article-title":"Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083","volume":"23","author":"Somlo","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/1078-0432.CCR-14-1552","article-title":"A Phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy in patients with advanced solid malignancies and peritoneal carcinomatosis","volume":"21","author":"Reiss","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1158\/1078-0432.CCR-14-2572","article-title":"Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program","volume":"21","author":"Smith","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Litton, J.K., Scoggins, M., Ramirez, D.L., Murthy, R.K., Whitman, G.J., Hess, K.R., Adrada, B.E., Moulder, S.L., Barcenas, C.H., and Valero, V. (2016). A pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a BRCA mutation. Ann. Oncol.","DOI":"10.1093\/annonc\/mdw364.10"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"43978","DOI":"10.18632\/oncotarget.6287","article-title":"PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia","volume":"6","author":"Ashleigh","year":"2015","journal-title":"Oncotarget"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"48794","DOI":"10.18632\/oncotarget.10720","article-title":"Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics","volume":"8","author":"Engert","year":"2017","journal-title":"Oncotarget"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1158\/1535-7163.MCT-13-0803","article-title":"Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib","volume":"13","author":"Murai","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Li, J., Zhou, N., Cai, P., and Bao, J. (2016). In Silico Screening Identifies a Novel Potential PARP1 Inhibitor Targeting Synthetic Lethality in Cancer Treatment. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17020258"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41598-016-0007-2","article-title":"Crystal structure-based discovery of a novel synthesized PARP1 inhibitor (OL-1) with apoptosis-inducing mechanisms in triple-negative breast cancer","volume":"6","author":"Fu","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/bjc.2016.67","article-title":"PARP inhibitors: The race is on","volume":"114","author":"Brown","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1200\/JCO.2009.27.5719","article-title":"Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer","volume":"28","author":"Konstantinopoulos","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/cbdd.12680","article-title":"Sirtuins are Unaffected by PARP Inhibitors Containing Planar Nicotinamide Bioisosteres","volume":"87","author":"Ekblad","year":"2016","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2174\/187152007781668715","article-title":"PARP Inhibitor Development for Systemic Cancer Targeting","volume":"7","author":"Zaremba","year":"2007","journal-title":"AntiCancer Agents Med. Chem."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Baptista, S.J., Silva, M.M.C., Moroni, E., Meli, M., Colombo, G., Dinis, T.C.P., and Salvador, J.A.R. (2017). Novel PARP-1 Inhibitor Scaffolds Disclosed by a Dynamic Structure-Based Pharmacophore Approach. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0170846"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1002\/jhet.2678","article-title":"Design, Synthesis, and Biological Evaluation of Some Cyclohepta[b]Thiophene and Substituted Pentahydrocycloheptathieno[2,3-d]Pyrimidine Derivatives","volume":"54","author":"Elmongy","year":"2017","journal-title":"J. Heter. Chem."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.bmcl.2013.02.032","article-title":"Design, synthesis and biological evaluation of novel imidazo[4,5-c]pyridinecarboxamide derivatives as PARP-1 inhibitors","volume":"23","author":"Zhu","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.2147\/OTT.S69935","article-title":"Profile of veliparib and its potential in the treatment of solid tumors","volume":"8","author":"Wagner","year":"2015","journal-title":"Onco. Targets Ther."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pharmthera.2016.02.003","article-title":"DNA repair targeted therapy: The past or future of cancer treatment?","volume":"160","author":"Gavande","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/0008-5472.CAN-13-1701","article-title":"Targeting PARP-1 allosteric regulation offers therapeutic potential against cancer","volume":"74","author":"Steffen","year":"2014","journal-title":"Cancer Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/18\/10\/2111\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:46:45Z","timestamp":1760208405000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/18\/10\/2111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,8]]},"references-count":100,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2017,10]]}},"alternative-id":["ijms18102111"],"URL":"https:\/\/doi.org\/10.3390\/ijms18102111","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,8]]}}}